JP2009542622A5 - - Google Patents

Download PDF

Info

Publication number
JP2009542622A5
JP2009542622A5 JP2009517603A JP2009517603A JP2009542622A5 JP 2009542622 A5 JP2009542622 A5 JP 2009542622A5 JP 2009517603 A JP2009517603 A JP 2009517603A JP 2009517603 A JP2009517603 A JP 2009517603A JP 2009542622 A5 JP2009542622 A5 JP 2009542622A5
Authority
JP
Japan
Prior art keywords
peptide
agent
seq
copolymer
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009517603A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009542622A (ja
JP5412280B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2007/000798 external-priority patent/WO2008001380A2/en
Publication of JP2009542622A publication Critical patent/JP2009542622A/ja
Publication of JP2009542622A5 publication Critical patent/JP2009542622A5/ja
Application granted granted Critical
Publication of JP5412280B2 publication Critical patent/JP5412280B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009517603A 2006-06-28 2007-06-28 加齢性黄斑変性症の治療法 Expired - Fee Related JP5412280B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80604106P 2006-06-28 2006-06-28
US60/806,041 2006-06-28
PCT/IL2007/000798 WO2008001380A2 (en) 2006-06-28 2007-06-28 Method of treatment of age-related macular degeneration

Publications (3)

Publication Number Publication Date
JP2009542622A JP2009542622A (ja) 2009-12-03
JP2009542622A5 true JP2009542622A5 (https=) 2010-09-24
JP5412280B2 JP5412280B2 (ja) 2014-02-12

Family

ID=38846104

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009517603A Expired - Fee Related JP5412280B2 (ja) 2006-06-28 2007-06-28 加齢性黄斑変性症の治療法

Country Status (7)

Country Link
US (1) US9089509B2 (https=)
EP (1) EP2046366B1 (https=)
JP (1) JP5412280B2 (https=)
AU (1) AU2007264682B2 (https=)
CA (1) CA2656463C (https=)
ES (1) ES2605154T3 (https=)
WO (1) WO2008001380A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075365A1 (en) * 2006-12-20 2008-06-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for treatment of age related degeneration of the retina
CA2752679A1 (en) * 2009-02-20 2010-08-26 The Scripps Research Institute Isolated monocyte populations and related therapeutic applications
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
WO2012143924A1 (en) 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
US20130217986A1 (en) * 2012-02-21 2013-08-22 Ucl Business Plc Method and system for predicting an amyloidosis status
WO2016183585A1 (en) * 2015-05-14 2016-11-17 Joslin Diabetes Center, Inc. Retinol-binding protein 3 (rbp3) as a protective factor in non-diabetic retinal degeneration
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
EP3565823B1 (en) * 2017-01-04 2024-05-29 Worg Pharmaceuticals (Zhejiang) Co., Ltd. S-arrestin peptides and therapeutic uses thereof
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
WO2000005249A2 (en) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
US20030149997A1 (en) * 1999-02-19 2003-08-07 Hageman Gregory S. Diagnostics and therapeutics for arterial wall disruptive disorders
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
JP4328050B2 (ja) * 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
US7399740B2 (en) * 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
US6524012B1 (en) * 2001-09-06 2003-02-25 Gkn Automotive, Inc. Securing members together by spring rings
ES2488766T3 (es) * 2002-01-25 2014-08-28 Biomedical Design, Inc. Fijación resistente a la calcificación
IL164202A0 (en) * 2002-03-26 2005-12-18 Yeda Res & Dev Use of an organ-specific pathogenic self-antigen for treatment of a non-autoimmune disease of said organ
US20060057110A1 (en) * 2002-06-14 2006-03-16 Yeda Research And Development Co. Ltd. Antigen-presenting cells for neuroprotection and nerve regeneration
US7860975B2 (en) * 2002-07-31 2010-12-28 Oracle America, Inc. System and method for secure sticky routing of requests within a server farm
US7354574B2 (en) * 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
ES2386435T3 (es) * 2003-01-07 2012-08-21 Yeda Research And Development Co., Ltd. Vacuna en forma de gotas oculares que contiene copolímero 1 para inmunización terapéutica

Similar Documents

Publication Publication Date Title
JP2009542622A5 (https=)
ES2598005T3 (es) Uso de IL-15 para aumentar la salida del timo y para tratar la linfopenia
KR101554056B1 (ko) 자가면역 질환의 치료 및/또는 예방 및 조절 ｔ세포의 형성을 위한 수단
DK2864360T3 (en) TARGETED THERAPY
ES2869155T3 (es) Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica
RU2012106150A (ru) Вариантные формы уратоксидазы и их применение
EP2848627A3 (en) Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
CA2355400A1 (en) Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
US20180044396A1 (en) Compounds and methods for modulating pharmacokinetics
JP2019530441A5 (https=)
CN104623639A (zh) 白介素22二聚体在制备治疗胰腺炎药物中的应用
EP2989121B1 (en) Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
CN117916257A (zh) 用于治疗自身免疫的工程化hla等位基因
JP2010535504A5 (https=)
JP2005511553A (ja) チモシンアルファ１ペプチド／ポリマー複合体
AU2019219072A1 (en) Modified immunomodulatory peptide
Taylor Modulation of regulatory T cell immunity by the neuropeptide alpha-melanocyte stimulating hormone
RU2011150283A (ru) Пептиды ттк и вакцины, их содержащие
RU2011140168A (ru) Пептиды vangl1 и содержащие их вакцины
Kozhich et al. Immunogenicity and immunopathogenicity of an autoimmune epitope are potentiated by increasing MHC binding through residue substitution
Briand et al. Emerging peptide therapeutics for inflammatory autoimmune diseases
US20160158330A1 (en) Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
EP2666782A1 (en) Coagulation factor VIII with reduced immunogenicity.
WO2025119999A1 (en) Extracellular vesicle based vaccine platform